This BioPhorum commentary summarizes the CGT industry views on PAT articulated during the virtual event, and highlights key takeaways on the benefits and barriers to PAT, unique considerations for PAT in the context of CGTs, and highlights some near-term options to help accelerate these important therapies to patients prior to implementing PAT.
PAT
Viewing related articles
PAT and Rapid Analytics supporting rapid manufacture survey
May 2023 | Benchmarking, Cell & Gene Therapy, Deliverable, Deliverables Report, PAT Monitoring and Control, POI - Cell and Gene Therapy
A BioPhorum member only benchmarking survey focusing on enabling rapid manufacture.
Survey to evaluate the current use of PAT software for chemometrics and PAT infrastructure
Apr 2023 | Benchmarking, Deliverable, Deliverables Report, Development Group, PAT Monitoring and Control, POI - Development Group
A BioPhorum member only survey that aims to tackle questions around the types of PAT software for chemometrics and PAT infrastructure used, ease of instalment, its advantages and limitations
Systematic assessment of process analytical technologies for biologics
Jun 2022 | Deliverable, Deliverables Report, Development Group, PAT Monitoring and Control, Publication
In order to evaluate the application of PAT tools to the development and commercialization of a bioprocess, BioPhorum conducted a benchmarking survey of biopharmaceutical companies and published the results in Biotechnology and Bioengineering journal. The results obtained in the survey can guide scientists and new manufacturers in terms of quality product development and all the stakeholders including funding agencies to assess the business value of tools and techniques employed during biologics manufacturing. This article published in Medicine Innovates is a synopsis of the paper
Systematic assessment of process analytical technologies for biologics
Nov 2021 | Deliverable, Development Group, PAT Monitoring and Control, Publication
To evaluate the application of PAT tools to the development and commercialization of a bioprocess, BioPhorum conducted a benchmarking survey of biopharmaceutical companies and published the results in Biotechnology and Bioengineering journal. Investigators assessed fifteen companies receiving seventeen responses from them and evaluated more than 20 different types of PAT tools in manufacturing using an industry-wide assessment to identify and rank the tools based on technological attributes such as technology maturity, ability to enable process control, and ease of implementation, as well as their business value such as simplicity of implementation, lead time, and cost reduction.
Attribute matrix on PAT for in-line monitoring and real-time release
Oct 2021 | Benchmarking, FF ILM/RTR, Fill Finish
A BioPhorum member only attribute matrix consisting of analysis of the current and desired state of PAT for ILM/RTR